Compare BTQ & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTQ | IMMX |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | Canada | United States |
| Employees | 35 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.4M | 716.2M |
| IPO Year | N/A | 2021 |
| Metric | BTQ | IMMX |
|---|---|---|
| Price | $3.49 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $19.20 |
| AVG Volume (30 Days) | 1.8M | ★ 1.8M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,332.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $1.94 |
| 52 Week High | $16.00 | $12.14 |
| Indicator | BTQ | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 41.06 |
| Support Level | $3.12 | $7.99 |
| Resistance Level | $3.80 | $8.97 |
| Average True Range (ATR) | 0.25 | 0.71 |
| MACD | 0.02 | -0.20 |
| Stochastic Oscillator | 62.33 | 10.42 |
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. The company derives revenue from Software licensing. Geographically, the company has a presence in Canada, Taiwan, Australia, and the United States.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.